SCHEDULE OF IMPACT OF RESTATEMENT (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Assets
Total assets	$ 159,008			$ 189,043			$ 159,008	$ 189,043	$ 137,638
Liabilities and stockholders’ equity
Total liabilities	1,243,578			2,332,959			1,243,578	2,332,959	3,249,500
Stockholders’ equity
Preferred stock, $0.001 par value	28,894						28,894
Common stock, $0.001 par value	82,239			144,355			82,239	144,355	145,642
Additional paid-in capital	17,103,158			12,913,571			17,103,158	12,913,571	13,012,670
Non-controlling interest				(659,063)				(659,063)	(680,886)
Accumulated deficit	(18,298,861)			(14,542,779)			(18,298,861)	(14,542,779)	(15,589,288)
Total stockholders’ equity	(1,084,570)	$ (1,099,956)	$ (990,361)	(2,143,916)	$ (2,662,182)	$ (4,060,523)	(1,084,570)	(2,143,916)	(3,111,862)	$ (3,292,546)
Total liabilities and stockholders’ equity	159,008			189,043			159,008	189,043	137,638
Loss from operations	(346,204)			(985,465)			(1,739,380)	(2,793,386)
Loss of issuance				(91,686)				(91,686)
Total other (expense) income								(600,227)
Net loss	(392,374)			(1,127,655)			(1,867,737)	(3,393,613)
Net loss attributable to the non-controlling interest			13,324	34,777	764	32,894	13,324	68,435
NET LOSS ATTRIBUTABLE TO BIOXYTRAN	$ (392,374)	$ (661,710)	$ (800,329)	$ (1,092,878)	$ (1,447,218)	$ (785,083)	$ (1,854,413)	$ (3,325,178)
Loss per Common share, basic	$ (0.00)			$ (0.01)			$ (0.01)	$ (0.03)
Loss per Common share, diluted	$ (0.00)			$ (0.01)			$ (0.01)	$ (0.03)
Weighted average number of Common shares outstanding, basic	126,391,176			136,443,056			153,821,016	129,441,332
Weighted average number of Common shares outstanding, diluted	126,391,176			136,443,056			153,821,016	129,441,332
Adjustment to reconcile net loss to net cash used in operating activities								$ 91,686
Net cash used in operating activities							$ (98,047)	(682,749)
Net cash used in investing activities							(17,867)	(37,740)
Net cash provided by financing activities							124,500	505,361
Net change in cash							$ 8,586	(215,128)
Previously Reported [Member]
Assets
Total assets				$ 189,043				189,043	137,638
Liabilities and stockholders’ equity
Total liabilities				2,332,959				2,332,959	3,249,500
Stockholders’ equity
Preferred stock, $0.001 par value
Common stock, $0.001 par value				144,355				144,355	145,642
Additional paid-in capital				12,821,885				12,821,885	12,920,984
Non-controlling interest				(659,063)				(659,063)	(680,886)
Accumulated deficit				(14,451,093)				(14,451,093)	(15,497,602)
Total stockholders’ equity				(2,143,916)				(2,143,916)	(3,111,862)
Total liabilities and stockholders’ equity				189,043				189,043	137,638
Loss from operations								(2,793,386)
Loss of issuance
Total other (expense) income								(508,541)
Net loss								(3,301,927)
Net loss attributable to the non-controlling interest								68,435
NET LOSS ATTRIBUTABLE TO BIOXYTRAN								$ (3,233,492)
Loss per Common share, basic								$ (0.02)
Loss per Common share, diluted								$ (0.02)
Weighted average number of Common shares outstanding, basic								129,441,332
Weighted average number of Common shares outstanding, diluted								129,441,332
Adjustment to reconcile net loss to net cash used in operating activities
Net cash used in operating activities								(682,749)
Net cash used in investing activities								(37,740)
Net cash provided by financing activities								505,361
Net change in cash								(215,128)
Revision of Prior Period, Reclassification, Adjustment [Member]
Assets
Total assets
Liabilities and stockholders’ equity
Total liabilities
Stockholders’ equity
Preferred stock, $0.001 par value
Common stock, $0.001 par value
Additional paid-in capital				91,686				91,686	91,686
Non-controlling interest
Accumulated deficit				(91,686)				(91,686)	(91,686)
Total stockholders’ equity
Total liabilities and stockholders’ equity
Loss from operations
Loss of issuance								(91,686)
Total other (expense) income								(91,686)
Net loss								(91,686)
Net loss attributable to the non-controlling interest
NET LOSS ATTRIBUTABLE TO BIOXYTRAN								$ (91,686)
Loss per Common share, basic								$ (0.01)
Loss per Common share, diluted								$ (0.01)
Weighted average number of Common shares outstanding, basic
Weighted average number of Common shares outstanding, diluted
Adjustment to reconcile net loss to net cash used in operating activities								$ 91,686
Net cash used in operating activities
Net cash used in investing activities
Net cash provided by financing activities
Net change in cash